# Phase 2 Anemia, Refractory, with: 20 recruiting (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials in phase 2 for Anemia, Refractory, with Excess of Blasts that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Anemia, Refractory, with Excess of Blasts trials: 20 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/anemia-refractory-with-excess-of-blasts

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 20
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 27, 2026 | NCT07896928 | Study of Allogeneic Stem Cell Transplant in Myelodysplastic Syndrome Following Conditioning With Fludarabine and Total Body Irradiation 800... | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | MDS, Myelodysplastic Syndrome MDS, Myelodysplastic Syndrome (MDS), Myelodysplastic Syndrome | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896928) |
| May 26, 2026 | NCT07607418 | Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS | Ruijin Hospital | Phase 2 | Recruiting | AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07607418) |
| February 10, 2026 | NCT07400341 | Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA | The First Affiliated Hospital of Soochow University | Phase 2 | Recruiting | MDS (Myelodysplastic Syndrome), Aplastic Anemia (AA) | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07400341) |
| November 25, 2025 | NCT07249346 | Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis... | Sponsor not shown (see the record) | Phase 2 | Recruiting | Leukemia, Myelodysplasia, Chronic Myelomonocytic Leukemia | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07249346) |
| October 9, 2025 | NCT07214064 | Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation | University Hospital Tuebingen | Phase 2 | Recruiting | AML (Acute Myeloid Leukemia), MDS/AML, MDS (Myelodysplastic Syndrome) | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07214064) |
| July 31, 2025 | NCT07096297 | Luspatercept + Darbepoetin in MDS | Yale University | Phase 2 | Recruiting | MDS (Myelodysplastic Syndrome) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07096297) |
| June 18, 2025 | NCT07025824 | Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation | Technische Universität Dresden | Phase 2 | Recruiting | AML - Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome) | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07025824) |
| March 24, 2025 | NCT06892223 | Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation | Istituto Clinico Humanitas | Phase 2 | Recruiting | Acute Myeloid Leukaemia, MDS (Myelodysplastic Syndrome), MPN (Myeloproliferative Neoplasms) | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06892223) |
| March 5, 2025 | NCT06859424 | A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With... | Center for International Blood and Marrow Transplant Research | Phase 2 | Recruiting | AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic... | 358 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06859424) |
| January 16, 2025 | NCT06778187 | Oral-ATO for TP53-mutated Myeloid Malignancies | The University of Hong Kong | Phase 2 | Recruiting | Acute Myeloid Leukemia, Myelodysplastic Neoplasm, Chronic Myelomonocytic Leukemia, TP53 Gene Mutation, Arsenic Trioxide | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06778187) |
| February 21, 2023 | NCT05735717 | MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies | Masonic Cancer Center, University of Minnesota | Phase 2 | Recruiting | Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, AML, TP53... | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05735717) |
| February 5, 2021 | NCT04741945 | Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS | Sponsor not shown (see the record) | Phase 2 | Recruiting | Preleukemia, Myelodysplastic Neoplasm, Cytopenia, Preleukemic Anemia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04741945) |
| November 25, 2020 | NCT04644016 | Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | AML, ALL, MDS, MPD Withou Myelofibrosis, NHL or HL, Inherited Metabolic Disorders, Hemoglobinopathies, Bone Marrow... | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04644016) |
| December 26, 2017 | NCT03383575 | Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Acute Myeloid Leukemia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia, IDH2 Gene... | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03383575) |
| October 19, 2017 | NCT03314974 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | Masonic Cancer Center, University of Minnesota | Phase 2 | Recruiting | Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma, Chronic Myelogenous Leukemia, Plasma... | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03314974) |
| April 5, 2016 | NCT02727803 | Personalized NK Cell Therapy in CBT | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02727803) |
| May 21, 2014 | NCT02143830 | HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy | Children's Hospital Medical Center, Cincinnati | Phase 2 | Recruiting | Fanconi Anemia, Severe Marrow Failure, Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML) | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02143830) |
| May 23, 2013 | NCT01861106 | Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations | National Cancer Institute (NCI) | Phase 2 | Recruiting | GATA2, Immunodeficiency, MDS | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01861106) |
| August 3, 2010 | NCT01174108 | Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized... | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | Recruiting | Severe Aplastic Anemia, MDS (Myelodysplastic Syndrome) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01174108) |
| December 3, 2008 | NCT00801489 | Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly... | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11... | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00801489) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| M.D. Anderson Cancer Center | 3 |
| Masonic Cancer Center, University of Minnesota | 2 |
| The University of Hong Kong | 1 |
| National Cancer Institute (NCI) | 1 |
| Center for International Blood and Marrow Transplant Research | 1 |
| University Hospital Tuebingen | 1 |
| Ruijin Hospital | 1 |
| Technische Universität Dresden | 1 |
| Yale University | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| Istituto Clinico Humanitas | 1 |
| National Heart, Lung, and Blood Institute (NHLBI) | 1 |
| The First Affiliated Hospital of Soochow University | 1 |
| Children's Hospital Medical Center, Cincinnati | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 13 |
| Germany | 2 |
| China | 2 |
| Denmark | 1 |
| Hong Kong | 1 |
| Italy | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Duplication companies in the United States](https://specstream.ai/data/businesses/duplication-companies/united-states)
- [Bars in the United States](https://specstream.ai/data/businesses/bars/united-states)
- [TV service providers in the United States](https://specstream.ai/data/businesses/tv-service-providers/united-states)
- [Product design firms in the United States](https://specstream.ai/data/businesses/product-design-firms/united-states)
- [Lighting fixtures and equipment companies in the United States](https://specstream.ai/data/businesses/lighting-fixtures-and-equipment-companies/united-states)
- [Fingerprinting services in the United States](https://specstream.ai/data/businesses/fingerprinting-services/united-states)
